IBA (Ion Beam Applications SA) shares its business update for Q3 2025, with equipment order intake at €195 million (+6% vs. last year) and a stable backlog of €1.3 billion. The company confirms its FY2025 REBIT guidance of at least €25 million. PanTera has started production at its Ac-225 facility, and IBA Clinical’s Proton Therapy division sees strong commercial activity and clinical evidence. Additionally, IBA Technologies reports solid progress in its various business sectors, with a focus on RadioPharma Solutions and industrial applications. The company also announced a €125 million refinancing package to strengthen its financial structure for future growth opportunities.

IBA’s performance year-to-date is on track with FY2025 guidance, and the company reiterates its mid-term outlook for 2024-2028, including revenue growth, OPEX, and REBIT targets. The company remains confident in its ability to deliver sustained profitability, despite external risks such as geopolitical developments. A €125 million club deal refinancing initiative was completed to optimize the balance sheet structure and support strategic investments. The company continues to monitor market conditions closely to adapt to challenges and opportunities.

Read more at GlobeNewswire: IBA is highly confident to meet